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OBJECTIVES: Chronic hepatitis B (CHB) is a major health problem in Taiwan where
an estimated two million people are infected with the virus, with many being
untreated. The disease is associated with a high risk of long term hepatic compli-
cations including cirrhosis and hepatocellular carcinoma (HCC). Treatment with
anti-virals such as entecavir reduces the risk of complications andmay lead to long
term cost savings. The aim of this economicmodelling studywas to investigate the
socioeconomic burden of untreated CHB in Taiwan and assess the economic ben-
efits of treatment. METHODS: A Markov model was developed that comprised
health states describing themanagement and consequences of CHB. Data from the
Taiwanese observational REVEAL cohort were used to estimate the risk of CHB
complications. Direct costs of complicationswere derived from literature and prev-
alence estimates were included to calculate the burden of disease amongst 30-59
year olds eligible for treatment in Taiwan. The model compared the economic
impact of doubling the number of eligible patients treated with entecavir on the
incidence of hepatic complications and associated costs. Themodelwas conducted
from a Taiwanese payer perspective with a 40 year time horizon. RESULTS: Treat-
ment of more eligible patients reduced the number of CHB complications over 40
years and was associated with a 1.06% (NTD 9.1 billion) reduction in total costs for
all diagnosed patients. Inclusion of productivity losses accentuated this with rela-
tive cost savings of 1.68% (NTD 17.2 billion). Based upon this setting, cost savings
would be realised by year 15. CONCLUSIONS: CHB is likely to have a substantial
economic impact over the next 40 years in Taiwan. Treating a greater proportion of
patients could alleviate this burden and lead to cost savings. Furthermore, treating
more patients is predicted to reduce productivity losses, improve quality of life,
and reduce mortality.
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OBJECTIVES: To estimate the budgetary consequence of adding Ustekinumab to
the reimbursement drug list in Thailand. METHODS: From payer’s perspective, a
5-year budget impact model was developed based on the current treatment algo-
rithm and reimbursement criteria for moderate to severe chronic plaque psoriasis.
We assumed the current biologic reimbursement program for psoriasis in civil
servant medical benefit scheme (CSMBS) was expanded to cover all Thai popula-
tion. Annual budget impact assessment was a result of changes of current mix of
biologic therapies by introduction of Ustekinumab. This use is as 1st or 2nd biologic
agent in patients with inadequate response from systemic therapies or other bio-
logics, respectively. Current and future market mix data of biologic therapies was
estimated by experts’ opinions, and products’ efficacy and epidemiology data was
derived from literature. Cost variables included medical care costs: biologic acqui-
sition costs, physician visits, monitoring lab tests and inadequate response care.
Univariate sensitivity analysis was conducted to assess the model robustness.
RESULTS: Ustekinumab’s inclusion showed the average total budget spending of
260 million baht per year (226 – 309 million baht from 1st - 5th year respectively).
Comparing to current scenarios with two biologics available, we found the dimi-
nution of total budget around 81 million baht in 5-yr period, accounting for 0.14
million baht per patient. Average budget growth rate was slightly lower with the
inclusion of Ustekinumab (9.90% vs. 11.75%). Comparative total cost per responder
was found lowest in Ustekinumab followed by Infliximab and Etanercept respec-
tively. These results weremainly driven by the number of patients on biologics and
distribution of patients among the available therapies. CONCLUSIONS: The addi-
tion of Ustekinumab to the current biologic reimbursement list provides more
efficient management approach for the treatment budget of moderate to severe
chronic plaque psoriasis in Thailand.
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OBJECTIVES: Systemic lupus erythematosus(SLE) is a chronic autoimmune disor-
der that may affect basically every organ of the body, such as the skin, joints,
kidneys, lungs and nervous system. The aim of this study was to demonstrate the
cost of organ damage cause by SLE. METHODS: A population-based dataset from
the Taiwan’s National Health Insurance Research Dataset (NHIRD) from 2006 to
2010 was used to collect SLE caused organ damage related medical cost. The cases
of SLE were identified according to the ICD-9-CM code 710.0 and catastrophic ill-
ness certificates. SLE related organ damage condition is defined based on the Sys-
temic Lupus International Collaborative Clinics/American Rheumatology (SLICC/
ACR) Damage Index, which contains 41 damage items in 12 systems that are
specific comorbidities associated with SLE or damage due to toxicity of SLE treat-
ment. ICD-9-CM codes were also used for organ damage conditions. To avoid dou-
ble-counting, SLE cases were only included if single comorbidity is observed.
RESULTS:A total number of 22,258 SLE patients were identified and used to extract
cost data of organ damage. Number of prevalent cases increased from 14,748 in
2006 to 18,047 in 2010, and prevalence rates permillion populations increased from
644.7 (623.0 after adjustment) in 2006 to 779.2 (729.9 after adjustment) in 2010.
Among 41 damage items, two of them (shrinking lung andminor tissue loss) do not
have corresponding ICD-9-CM codes. Recurrent cerebral vascular accident or re-
section, cardiomyopathy, and recurrent myocardial infarction caused most medi-
cal expenditures, and mean costs incurred in the first year were NT$ 502,171, NT$
498,871, and NT$ 357,979, respectively. CONCLUSIONS: Organ damages caused by
SLE have incurred tremendous resource utilization to health care system in Tai-
wan. New treatment which can avoid organ damages with neuropsychiatric, renal
and cardiovascular systems is needed for SLE patients.
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OBJECTIVES: Parenteral nutrition is a form of nutritional support administered via
an intravenous catheter. Kabiven is a simple TPN solution that consists of a three
chamber bag and the individual chambers contain glucose- and amino acid solu-
tions, and fat emulsion, respectively. Kabiven may effect serum albumin levels for
malnutrition patient and cost savings to patients receiving tradition TPN.
METHODS: This was a retrospective study in a regional hospital from January 1,
2011 to December 31, 2011. We collected data on patients admitted to ward care
programs who are consulted TPN group for nutrition suggest, a total 164 who are
consulted TPN group than received kabiven for nutrition support during their hos-
pitalization.Monitor serumalbuminwas performed before and after kabiven given
were rospective criteria. RESULTS: The 164 patient included 108 male ( 65.9%) and
56 female (34.1%) GAverage length of stay was 14.3 days (10-30 days; 51.2%) GAver-
age age at 77.2y/o (70-79y/o,33%). The result elevated serum albumin levels 39%(
1.2 g/dl, 25% G0.8 g/dl, 17%G0.7 g/dl, 15%), same serum albumin level 44%,
decrease serum albumin levels 17%. CONCLUSIONS: This study demonstrated that
the simple TPN solutions (kabiven) may significant elevated serum albumin levels
for malnutrition patient and significant cost savings to patients receiving tradition
TPN.
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OBJECTIVES: To describe the prevalence and the treatment status of hemophilia A
(HA), hemophilia B (HB) andVonWillebrand disease (VWD) in India, Russia, Taiwan
and Turkey based on existing data, and to compare prophylaxis with on-demand
therapy. METHODS: We conducted a systematic literature review in Aug, 2011
using PubMed, EMBASE, and Cochrane Library. No retrieval limitation was set. We
also carried out general and targeted internet searches of hemophilia related web-
sites. Reference lists of key reviews were hand-searched for further researches.
Studies providing data of prevalence, treatment or cost of hemophilia in India,
Russia, Taiwan and Turkey were included. Noteexpress 2 was used to manage the
literatures. Meta-analysis was done using the generic inverse variance model.
RESULTS:Overall, 7 epidemiological and 15 economic studieswere included for the
analysis. The prevalence of hemophilia in India, Russia, Taiwan and Turkey was
2.27 per 100 000 (HAHB), 5.12 per 100 000 (HAHBVWD), 3.61 per 100 000 (HA)
and 4.93 per 100 000 (HAHBVWD) respectively. In India, about 15% patients
received no treatment, 47.5% patients used previous blood transfusion, 12.5% used
cryoprecipitate and 25% used factor concentrate. 37% of patients used prophylaxis
in Russia. In Turkey, prophylaxis was superior to on-demand therapy even when
given in a twice-weekly period with intermediate concentrates. Annual extra ex-
penditure of below $5000 per case with prophylaxis compared to on-demand ther-
apywould be needed to permit hemophiliac children to achieve similar capacity as
unaffected ones. In Taiwan, approximately $2 million per year would be added to
the cost of treatment by having all severe HA patients receive secondary prophy-
laxis instead of on-demand therapy while 12566 bleeding would be prevented.
CONCLUSIONS: The prevalence of hemophilia is different among those 4 districts.
Hemophiliacs lack adequate treatment generally. It is practical to switch from
on-demand therapy to Prophylaxis.
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OBJECTIVES: To explore peri-operative bleeding and its relationship with patient
morbidity, mortality and increased health care costs in Hong Kong. METHODS:
EMBASE andMedline databaseswere searched to identify relevant epidemiological
and economic studies. To ensure pertinence of the data, only studies published in
the last 15 years were considered. Relevant studies were identified using a priori
defined inclusion criteria relating to the patient population, setting and outcomes
of interest. RESULTS: Eighteen studies were included in this systematic review.
Themean volume of blood loss ranged from 20–2200mL. Laparoscopic procedures
were generally associated with lower blood loss (20–350 mL), while orthognathic
and liver surgery were associated with greater blood loss (600–2200 mL). Similarly,
the mean volume of blood transfused varied by surgical procedure ranging from
0.17 units (head and neck surgery) to 1.8 units (orthognathic surgery).With the cost
of 1 unit of whole blood estimated at US$200 in Hong Kong, the need for transfu-
sions potentially represent a substantial cost to patients and the health care sys-
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tem. The transfusion of blood during surgery was associated with increased risk of
wound infection (OR 1.92–3.82, p0.02), post-operative complications (OR 2.63,
p0.001) and increasedmortality (OR 1.6–10.2, p0.05). Peri-operative blood trans-
fusionwas also associatedwith an increasedhospital stay of 4.1 days inHongKong,
equating to approximately US$4300 in excess hospital expenses. CONCLUSIONS:
This review has identified several areas in which peri-operative bleeding may in-
crease the burden to the Hong Kong health care system. This includes the greater
need for transfusions, risk of complications and extended hospital stay. Accord-
ingly, improvements in haemostasis have the potential to reduce direct health care
resource utilisation through a reduction in blood use, hospital length of stay, need
for additional procedures and patient mortality.
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OBJECTIVES: Fibromyalgia is a neuropathic syndrome which is more common in
adult females. Pregabalin is the first medicine which was approved by FDA for
treatment of fibromyalgia. In this study we aim to evaluate the cost- effectiveness
of pregabalin in the treatment of fibromyalgia in Iran.METHODS: To evaluate the
efficacy of pregabalin, a systematic review by searching on PubMed, Scopus and
Google scholar was conducted. The keywords included “fibromyalgia” and “prega-
balin”. The outcome of interest in the reports was the score pain. To evaluate costs
of treatment, the direct costs were considered. RESULTS: Out of 8994 primary
reports only three reports were included in the study which all of them were
Randomized Clinical Trial with placebo control. Considering the efficacy extracted
from the reports, the ICER for each treatment doses was calculated. In pregabalin
450 mg/day, the ICER for domestic generic medicine was 0.72 dollar per day per
pain score reduction and for imported brand (Lyrica) was 6.47 dollar per day per
pain score reduction and for pregabalin 600 m/day these results were 0.78 and 5.53
respectively. CONCLUSIONS: Our analysis indicated that pregabalin in the treat-
ment doses of 300, 450, 600 mg/day is cost- effective and could be included into
insurance positive list.
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OBJECTIVES:Conventional treatment of organophosphate (OP) poisoningwith oxi-
mes has had limited success. Fresh frozen plasma (FFP), acting as a bioscavenger to
clean up free OP has been recently proposed as a treatment. In this study, we
undertook a meta-analysis to evaluate the efficacy of FFP in management of OP
poisoning to explore if this bioscavenger therapy can be effective and cost saving in
health system or not.METHODS: All relevant databases were searched (till Febru-
ary 2012) for all clinical effects of FFP in OP poisoning. The inclusion criteria were
death, development of intermediate syndrome, need for ventilation, and adverse
effects. Cost data were collected from standard cost list. Cost-effectiveness grid of
adding on FFP was calculated per consequence and compared with the conven-
tional regimen. RESULTS:A total of 3 studies and 157 patients were included in the
meta-analysis. Overall, we did not find significant effectiveness for FFP to prevent
death (RR 1.01, 95% CI 0.32-3.4) or intermediate syndrome (RR 0.67, 95% CI 0.04-
12.39). Since FFP in Iran is provided free of charge, the 
 cost is zero. Considering
direct cost and clinically important differences between effectiveness of FFP sup-
plementing and conventional therapy (
 effectiveness (for avoiding intermediate
syndrome)  7), however economics evaluations is not necessary according to
cost-effectiveness grid but it could be considered dominate. CONCLUSIONS: Re-
sults do not support significant efficacy of FFP in reduction of death or intermediate
syndrome in patientswith OP poisoning. FFP use, however, has no impact in health
cost; by consideration of only direct costs; the possibility of its benefit in lowering
rate of intermediate syndrome in terms of productivity loss and indirect cost
should be considered in future studies.
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OBJECTIVES: Bone Marrow transplantation is the only therapeutic option that can
cure thalassemia disease. Reduced intensity hematopoietic stem cell transplanta-
tion (RI-HSCT) has demonstrated a high cure rate with minimal complications
compared to other options. Because RI-HSCT is very costly, economic justification
for its value is needed. This study aimed to estimate the cost-utility of RI-HSCT
compared with blood transfusions combined with iron chelating therapy (BT-ICT)
for adolescent and young adult with severe thalassemia in Thailand.METHODS: A
Markov model was used to estimate the relevant costs and health outcomes over
the patients’ lifetimes using a societal perspective. All future costs and outcomes
were discounted at a rate of 3% per annum. The efficacy of RI-HSCT was based a
clinical trial including a total of 18 thalassemia patients. Utility valueswere derived
directly from all patients using EQ-5D and SF-6D. Primary outcomes of interest
were lifetime costs, quality adjusted life-years (QALYs) gained, and the incremen-
tal cost-effectiveness ratio (ICER) in Thai baht (THB) per QALY gained. One-way and
probabilistic sensitivity analyses (PSA) were conducted to investigate the effect of
parameter uncertainty. RESULTS: In base case analysis, the RI-HSCT group had a
better clinical outcomes and higher lifetime costs. The incremental cost per QALY
gained was 99,548 baht. The acceptability curve showed that the probability of
RI-HSCT being cost-effective was 64% at the willingness to pay of 1 time of Thai
Gross domestic product per capita (GDP per capita), approximately US$4210 per
QALY gained. Themost sensitive parameter is discounting rate. CONCLUSIONS:At
a societal willingness to pay of 1 GDP per capita, RI-HSCT was a cost-effective and
affordable treatment for adolescent and young adult with severe thalassemia in
Thailand compared to BT-ICT.
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OBJECTIVES: To assess the incremental cost-effectiveness ratios of Immune Tol-
erance Induction (ITI) therapy with plasma derived FVIII concentrates versus on-
demand treatmentwith Recombinant FVIIa (rFVIIa) in hemophilia Awith high titer
inhibitors from Ministry of Health perspective of Iran. METHODS: This study was
based on the study of Knight et al, which evaluated the cost-effectiveness ratios of
different treatment for hemophilia A with high-responding inhibitors. To adapt
Knight’ Results to the Iranian context, a few clinical parameters were varied and
cost data were replaced with the corresponding Iranian estimates of resource use.
The time horizon of the analysis was 10 years. One-way sensitivity analyses were
performed varying the cost of the clotting factor, the drug dose, and the adminis-
tration frequency to test the robustness of the analysis. RESULTS: Comparison of
the incremental cost-effectiveness ratios (ICERs) between the three ITI protocols
and the On-Demand regimen with rFVIIa show that all three ITI protocols domi-
nates On-Demand regimen with rFVIIa between ITI protocols the Low-Dose ITI
protocol dominates both the Bonn ITI protocol and the Malmö ITI protocol, would
also be preferred ITI protocol. All of three ITI protocols dominate the On-Demand
strategy as they have both a lower average lifetime cost and higher QALYs gained.
The cost per QALY gained for the Bonn ITI protocol compared with the Malmö ITI
protocol was $249,391.84. The cost per QALY gained for the Bonn ITI protocol com-
pared with the Low-Dose ITI protocol was $842,307.69. CONCLUSIONS: The results
of data derived fromour study suggest that The Low-Dose ITI protocolmay be a less
expensive and/or cost-effective option compared with on-demand first-line treat-
ment with rFVIIa.
SYSTEMIC DISORDERS/CONDITIONS - Patient-Reported Outcomes & Patient
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OBJECTIVES: Treatment for haemophilia inhibitor patients has improved substan-
tially since the 1980’s and 1990’s. But from a health economic perspective, an
unmet need persists for better treatment options in terms of health-related quality
of life (HRQoL) and cost savings. Haemostatic products alone account for the big-
gest expense in the care of haemophilia patients. Congenital haemophilia with
inhibitors involves lifelong treatment, and with it, substantial long-term costs and
lowered HRQoL. METHODS: A systematic review on cost and HRQoL findings for
haemophilia treatments in economic terms was conducted on more than 280 sci-
entific studies. Fifty-five articles were retained for the execution of the project
analysis. RESULTS: The analysis shows that to counteract costs to payers (society)
and to improve patient outcomes, improved treatments could increase HRQoL.
This could be achieved with FVIII and FIX bypassing agents that have: greater
convenience through subcutaneous administration (less-painful injections, avoid-
ance of infusions), faster onset through a fast-acting rFVIIa analogue (faster reso-
lution of bleeding episodes leading to faster pain relief, sustained control, less
dosing), and longer duration through a long-acting rFVIIa derivative (fewer injec-
tions and rebleeds, arthropathy prevention). CONCLUSIONS: Improved FVIII/IX
bypassing agents for treatment of haemophilia patients with inhibitors would be a
cost-effective option for society, improving HRQoL associated with the clinical
condition.
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OBJECTIVES: There are large gaps in hemophilia treatment standards around the
world. Among developing nations, disparities in care exist resulting in sub-optimal
outcomes for patients in some countries. The objective of this analysis was to
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